This page is an archive. Its content may no longer be accurate and was last updated on the original publication date. It is intended for reference and as a historical record only. For hep C questions, call Help4Hep BC at 1-888-411-7578.
EDISON, N.J., May 30, 2018 (GLOBE NEWSWIRE) — ContraVir Pharmaceuticals Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of hepatitis B virus (HBV), announced today new findings confirming that CRV431, a cyclophilin inhibitor, reduces the number and size of liver tumors in a hepatocellular carcinoma (HCC) mouse model.
Data from the study indicate that CRV431 reduced the number of tumor nodules by 44% and reduced the overall tumor burden by 56% (composite score based on tumor number and size) compared to the vehicle control group (p=0.02). Importantly, 25% of CRV431-treated mice had no liver tumors at the end of the 10 week study, whereas all vehicle-treated mice had at least five tumors per liver.
“The results of this preclinical study indicate that CRV431 could offer a potential treatment opportunity for hepatocellular carcinoma (HCC), representing an important pipeline expansion opportunity for ContraVir,” commented James Sapirstein, Chief Executive Officer of ContraVir. “We previously demonstrated that CRV431 reduces key markers of hepatitis B virus (HBV) including DNA, HBsAg, and pgRNA. This new data provides evidence that CRV431 can also reduce the amount and size of tumors in HCC, bringing us another step closer to our ultimate goal of reducing the burden of liver disease.”
Read the complete press release here: https://globenewswire.com/news-release/2018/05/30/1513828/0/en/ContraVir-Pharmaceuticals-Cyclophilin-Inhibitor-CRV431-Reduces-Development-and-Progression-of-Liver-Tumors-in-Preclinical-Hepatocellular-Carcinoma-Study.html